Related Experiment Video
Updated: Jul 1, 2025
Visualizing DNA Damage Repair Proteins in Patient-Derived Ovarian Cancer Organoids via Immunofluorescence Assays
Published on: February 24, 2023
PARP Inhibitors: Strategic Use and Optimal Management in Ovarian Cancer
Nicholas Hirschl1, Wildnese Leveque1, Julia Granitto1
1Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA.
Abstract:
Poly (ADP-ribose) polymerase (PARP) inhibitors have become an established part of the anticancer armamentarium. Discovered in the 1980s, PARP inhibitors (PARPis) were initially developed to exploit the presence of BRCA mutations, which disrupt the homologous recombination repair of deoxyribonucleic acid (DNA) via synthetic lethality, an intrinsic vulnerability caused by the cell's dependence on other DNA repair mechanisms for which PARP is an essential contributor. PARPi use expanded with the demonstration of clinical benefit when other mechanisms of high-fidelity DNA damage response were present in cancer cells called homologous repair deficiency (HRD). Recently, new data have resulted in the voluntary withdrawal of later-line treatment indications for all the available PARPis used in ovarian cancer because of a negative impact on overall survival (OS). PARPi switch maintenance to consolidate a response to platinum-based therapy is recommended for earlier treatment lines to have the greatest impact on the chance of cure and length of survival. This article reviews the clinical utility of PARPis and how to integrate them into best practices.
Insights
Poly (ADP-ribose) polymerase (PARP) inhibitors are vital anticancer drugs. While effective for BRCA mutations and homologous repair deficiency (HRD), recent data led to withdrawals in later-line ovarian cancer treatment due to overall survival concerns.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) exploit DNA repair defects, particularly BRCA mutations, through synthetic lethality.
- PARPi efficacy is linked to homologous repair deficiency (HRD) in cancer cells.
- Recent clinical data have impacted the use of PARPis in ovarian cancer.
Purpose of the Study:
- To review the clinical utility of PARP inhibitors.
- To discuss the integration of PARPis into optimal cancer treatment strategies.
- To address recent changes in PARPi indications.
Main Methods:
- Review of clinical trial data and scientific literature on PARP inhibitors.
- Analysis of mechanisms of action, including synthetic lethality and HRD.
- Evaluation of treatment guidelines and recent regulatory actions.
Main Results:
- PARPis are established anticancer agents, particularly effective in BRCA-mutated and HRD-positive cancers.
- Withdrawal of later-line indications for PARPis in ovarian cancer due to negative overall survival impact.
- PARPi switch maintenance is recommended for earlier treatment lines to improve cure rates and survival.
Conclusions:
- PARP inhibitors remain important in oncology, but their application requires careful consideration of treatment lines and patient populations.
- Optimizing PARPi use involves strategic integration into earlier treatment phases, especially post-platinum therapy.
- Ongoing research is crucial to refine PARPi utility and address survival outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:34Inhibition of Cdk Activity